GUJTHEMPharmaceuticals
Gujarat Themis Biosyn Ltd — Cash Flow Statement
₹226.90
-6.10%
Gujarat Themis Biosyn Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Depreciation | 5.65 Cr | 4.06 Cr | 2.58 Cr | 2.23 Cr | — |
| Free Cash Flow | -25.12 Cr | -10.43 Cr | 15.77 Cr | 26.42 Cr | — |
| Issuance Of Debt | 29.89 Cr | 0.00 | — | — | 0.00 |
| Capital Expenditure | -116.15 Cr | -74.64 Cr | -23.70 Cr | -13.90 Cr | — |
| End Cash Position | 11.69 Cr | 6.47 Cr | 6.05 Cr | 0.46 Cr | — |
| Beginning Cash Position | 6.47 Cr | 6.05 Cr | 0.26 Cr | 3.97 Cr | — |
| Changes In Cash | 5.22 Cr | 0.41 Cr | 5.79 Cr | -3.51 Cr | — |
| Financing Cash Flow | 26.01 Cr | -8.59 Cr | -13.27 Cr | -14.00 Cr | — |
| Net Other Financing Charges | 1000.00 | — | — | 1000.00 | 1000.00 |
| Interest Paid Cff | -0.43 Cr | -0.09 Cr | -0.09 Cr | -0.21 Cr | — |
| Cash Dividends Paid | -1.82 Cr | -6.90 Cr | -12.44 Cr | -10.00 Cr | — |
| Net Issuance Payments Of Debt | 29.89 Cr | 0.00 | 0.00 | -3.07 Cr | — |
| Net Long Term Debt Issuance | 29.89 Cr | 0.00 | 0.00 | -3.07 Cr | — |
| Long Term Debt Issuance | 29.89 Cr | 0.00 | — | — | 0.00 |
| Investing Cash Flow | -111.82 Cr | -55.21 Cr | -20.41 Cr | -29.83 Cr | — |
| Net Other Investing Changes | -1000.00 | — | — | 1000.00 | — |
| Interest Received Cfi | 4.33 Cr | 2.69 Cr | 3.28 Cr | 1.57 Cr | — |
| Net PPE Purchase And Sale | -116.15 Cr | -74.64 Cr | -23.70 Cr | -13.90 Cr | — |
| Purchase Of PPE | -116.15 Cr | -74.64 Cr | -23.70 Cr | -13.90 Cr | — |
| Operating Cash Flow | 91.03 Cr | 64.21 Cr | 39.48 Cr | 40.31 Cr | — |
| Taxes Refund Paid | -16.49 Cr | -19.78 Cr | -20.42 Cr | -14.52 Cr | — |
| Change In Working Capital | 36.88 Cr | 4.19 Cr | -15.11 Cr | -4.36 Cr | — |
| Change In Other Current Liabilities | 0.51 Cr | -0.12 Cr | -2.46 Cr | 1.51 Cr | — |
| Change In Other Current Assets | 37.39 Cr | 1.64 Cr | -19.84 Cr | 6.86 Cr | — |
| Change In Payable | 4.79 Cr | 0.37 Cr | 2.93 Cr | 3.14 Cr | — |
| Change In Inventory | -1.72 Cr | 11.29 Cr | -3.01 Cr | -5.56 Cr | — |
| Change In Receivables | -4.21 Cr | -9.12 Cr | 7.21 Cr | -10.40 Cr | — |
| Other Non Cash Items | -0.51 Cr | -3.60 Cr | -4.98 Cr | -2.31 Cr | — |
| Depreciation And Amortization | 5.65 Cr | 4.06 Cr | 2.58 Cr | 2.23 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -0.05 Cr | 0.00 | 0.00 | -94000.00 | — |
| Net Income From Continuing Operations | 65.54 Cr | 79.33 Cr | 77.46 Cr | 59.03 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | -1000.00 | 1000.00 | — | — |
| Interest Paid Cfo | — | -0.08 Cr | -0.05 Cr | — | — |
| Repayment Of Debt | — | — | 0.00 | -3.07 Cr | -2.01 Cr |
| Long Term Debt Payments | — | — | 0.00 | -3.07 Cr | -2.01 Cr |
| Provisionand Write Offof Assets | — | — | 0.00 | 0.24 Cr | 0.00 |
| Net Investment Purchase And Sale | — | — | — | 0.00 | 50000.00 |
| Sale Of Investment | — | — | — | 0.00 | 50000.00 |
| Sale Of PPE | — | — | — | 0.00 | 0.01 Cr |
| Common Stock Dividend Paid | — | — | — | — | -2.40 Cr |
| Net Short Term Debt Issuance | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Gujarat Themis Biosyn Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.